Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/218304
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMarín-Quintero, D.-
dc.contributor.authorFernández Campos, Francisco-
dc.contributor.authorCalpena Campmany, Ana Cristina-
dc.contributor.authorMontes López, María Jesús-
dc.contributor.authorClares Naveros, Beatriz-
dc.contributor.authorPozo Carrascosa, Alfonso del-
dc.date.accessioned2025-01-31T09:44:32Z-
dc.date.available2025-01-31T09:44:32Z-
dc.date.issued2013-11-22-
dc.identifier.issn0022-3549-
dc.identifier.urihttps://hdl.handle.net/2445/218304-
dc.description.abstractABSTRACT: Nystatin (NYS) is a polyene macrolide with broad antifungal spectrum restricted to topical use owing to its toxicity upon systemic administration. The aims of thiswork were the design, development, and optimization ofNYS-loaded lipid emulsion for intravenous administration. A closed circuit system was designed to apply ultrasound during the elaboration of the lipid intravenous emulsions (LIEs). Additionally, a comparison with the commercially available Intralipid R 20% was also performed.Manufacturing conditions were optimized by factorial design. Formulations were evaluated in terms of physicochemical parameters, stability, release profile, and antimicrobial activity. The average droplet size, polydispersity index, zeta-potential, pH, and volume distribution values ranged between 192.5 and 143.0 nm, 0.170 and 0.135, −46 and −44 mV, 7.11 and 7.53, 580 and 670 nm, respectively. The selected NYS-loaded LIE (NYS-LIE54) consisted of soybean oil (30%), soybean lecithin (2%), solutol HSR 15 (4%), and glycerol (2.25%) was stable for at least 60 days. In vitro drug release studies of this formulation suggested a sustained-release profile. Equally, NYS-LIE54 showed the best antimicrobial activity being higher than the free drug. Thus, it could be a promising drug delivery system to treat systemic fungal infections. C 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci Keywords: drug design; nystatin; lipids; emulsion; injectables; surfactants; candida; aspergillus; mathematical model-
dc.format.extent9 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherWiley-
dc.relation.isformatofVersió postprint del document publicat a:-
dc.relation.ispartofJournal of Pharmaceutical Sciences, 2013, vol. 102, num.11, p. 4015-4023-
dc.rights(c) The American Pharmacists Association, 2013-
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)-
dc.subject.classificationLípids-
dc.subject.classificationEmulsions-
dc.subject.otherLipids-
dc.subject.otherEmulsions-
dc.titleFormulation Design and Optimization for the Improvement of Nystatin-Loaded Lipid Intravenous Emulsion-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.identifier.idgrec628184-
dc.date.updated2025-01-31T09:44:32Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
166012.pdf848.68 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.